Search Result

Results for "

gemcitabine

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Linker (1) Akt (3) Aldose Reductase (1) Antibiotic (1) Apoptosis (36) Aurora Kinase (2) Autophagy (11) Bacterial (1) Bcl-2 Family (1) c-Fms (2) Caspase (3) CDK (3) Checkpoint Kinase (Chk) (9) DNA/RNA Synthesis (18) Drug Derivative (5) Drug Metabolite (5) Drug-Linker Conjugates for ADC (2) EGFR (1) Endogenous Metabolite (2) Enterovirus (1) Epigenetic Reader Domain (1) ERK (1) FGFR (2) FLT3 (2) Glycosidase (1) HDAC (6) HIF/HIF Prolyl-Hydroxylase (1) HSV (1) Influenza Virus (2) Integrin (1) Isotope-Labeled Compounds (5) JNK (1) Keap1-Nrf2 (1) MDM-2/p53 (3) MMP (1) mTOR (2) Necroptosis (1) NF-κB (2) Nucleoside Antimetabolite/Analog (14) P2Y Receptor (1) p38 MAPK (1) PAI-1 (2) PI3K (1) PKC (1) RAD51 (2) Reactive Oxygen Species (ROS) (1) Reference Standards (5) RET (2) Ribosomal S6 Kinase (RSK) (1) SARS-CoV (1) Ser/Thr Protease (2) Sirtuin (2) Src (3) VEGFR (2) Wee1 (2) Wnt (1)
By Research Areas:	Cancer (65) Endocrinology (2) Infection (6) Inflammation/Immunology (7) Neurological Disease (2)

By Targets:

ADC Linker (1)

Akt (3)

Aldose Reductase (1)

Antibiotic (1)

Apoptosis (36)

Aurora Kinase (2)

Autophagy (11)

Bacterial (1)

Bcl-2 Family (1)

c-Fms (2)

Caspase (3)

CDK (3)

Checkpoint Kinase (Chk) (9)

DNA/RNA Synthesis (18)

Drug Derivative (5)

Drug Metabolite (5)

Drug-Linker Conjugates for ADC (2)

EGFR (1)

Endogenous Metabolite (2)

Enterovirus (1)

Epigenetic Reader Domain (1)

ERK (1)

FGFR (2)

FLT3 (2)

Glycosidase (1)

HDAC (6)

HIF/HIF Prolyl-Hydroxylase (1)

HSV (1)

Influenza Virus (2)

Integrin (1)

Isotope-Labeled Compounds (5)

JNK (1)

Keap1-Nrf2 (1)

MDM-2/p53 (3)

MMP (1)

mTOR (2)

Necroptosis (1)

NF-κB (2)

Nucleoside Antimetabolite/Analog (14)

P2Y Receptor (1)

p38 MAPK (1)

PAI-1 (2)

PI3K (1)

PKC (1)

RAD51 (2)

Reactive Oxygen Species (ROS) (1)

Reference Standards (5)

RET (2)

Ribosomal S6 Kinase (RSK) (1)

SARS-CoV (1)

Ser/Thr Protease (2)

Sirtuin (2)

Src (3)

VEGFR (2)

Wee1 (2)

Wnt (1)

By Research Areas:

Cancer (65)

Endocrinology (2)

Infection (6)

Inflammation/Immunology (7)

Neurological Disease (2)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-17026

*Gemcitabine* Maximum Cited Publications 266 Publications Verification LY 188011	Nucleoside Antimetabolite/Analog DNA/RNA Synthesis Autophagy Apoptosis p38 MAPK	Infection Inflammation/Immunology Cancer
Gemcitabine (LY 188011) is a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent. Gemcitabine inhibits DNA synthesis and repair, and can modulate autophagy. Gemcitabine induces apoptosis through the activation of p38 MAPK. Gemcitabine demonstrates efficacy in mouse models of pancreatic and breast cancer. Gemcitabine can be used for cancer research, such as pancreatic cancer, non-small cell lung cancer, and breast cancer .

HY-B0003

Gemcitabine hydrochloride Maximum Cited Publications 266 Publications Verification LY 188011 hydrochloride	DNA/RNA Synthesis Nucleoside Antimetabolite/Analog Autophagy Apoptosis	Cancer
Gemcitabine Hydrochloride (LY 188011 Hydrochloride) is a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent. Gemcitabine Hydrochloride inhibits DNA synthesis and repair, resulting in autophagyand apoptosis .

HY-160818

MC3138 2 Publications Verification	Sirtuin	Cancer
MC3138 is a selective SIRT5 activator. MC3138 has antitumor activity on human PDAC cells, with IC₅₀ values of 25.4-236.9 μM. MC3138 combined with Gemcitabine (HY-17026) significantly inhibits tumor growth in mice .

HY-13538

Gemcitabine elaidate 5 Publications Verification CP-4126; CO-101; gemcitabine 5'-elaidate	Nucleoside Antimetabolite/Analog Autophagy Apoptosis	Inflammation/Immunology Cancer
Gemcitabine elaidate (CP-4126) is lipophilic pro-agent of Gemcitabine. Gemcitabine elaidate is converted to Gemcitabine by esterases in order to be phosphorylated. Gemcitabine elaidate exhibits anti-tumor activity .

HY-138253

2′,2′-Difluorodeoxyuridine dFdU; 2',2'-Difluoro-2'-deoxyuridine	Drug Metabolite Apoptosis	Cancer
2’,2’-Difluorodeoxyuridine (dFdU) is the main metabolite of Gemcitabine (HY-17026). 2’,2’-Difluorodeoxyuridine causes a concentration- and schedule- dependent radiosensitising effect in vitro. 2’,2’-Difluorodeoxyuridine arrests cell cycle at the early S phase and induces apoptosis in cancer cells .

HY-100885

Acelarin 1 Publications Verification NUC-1031	DNA/RNA Synthesis	Cancer
Acelarin (NUC-1031) is a ProTide transformation and enhancement of the widely-used nucleoside analogue, gemcitabine.

HY-10032

PF 477736 4 Publications Verification PF 00477736	Checkpoint Kinase (Chk) VEGFR Src c-Fms Aurora Kinase FGFR FLT3 RET CDK	Cancer
PF 477736 (PF 00477736) is a potent, selective and ATP-competitive inhibitor of Chk1, with a K_i of 0.49 nM, it is also a Chk2 inhibitor, with a K_i of 47 nM. PF 477736 shows <100-fold selectivity for Chk1 over VEGFR2, Fms, Yes, Aurora-A, FGFR3, Flt3, and Ret (IC₅₀=8 (K_i), 10, 14, 23, 23, 25, and 39 nM, respectively). PF 477736 can enhance Gemcitabine antitumor activity in vitro and in vivo .

HY-P9964

Necitumumab 11F8; IMC-11F8; LY3012211	EGFR	Cancer
Necitumumab (11F8; IMC-11F8; LY3012211) is a human IgG monoclonal antibody directed against EGFR. Necitumumab binds to the EGF binding site of EGFR, blocks ligand binding, neutralizes ligand-induced EGFR phosphorylation and downstream signaling, induces EGFR internalization and degradation, and mediates antibody-dependent cellular cytotoxicity (ADCC) in EGFR-expressing cells. Necitumumab enhances antitumour activity in combination with Gemcitabine (HY-17026) and Cisplatin (HY-17394) in murine non-small-cell lung cancer xenograft models. Necitumumab can be used in research on cancers such as non-small cell lung cancer and colorectal cancer .

HY-17026R

Gemcitabine (Standard) LY 188011 (Standard)	Reference Standards Nucleoside Antimetabolite/Analog DNA/RNA Synthesis Autophagy Apoptosis	Cancer
Gemcitabine (Standard) is the analytical standard of Gemcitabine. This product is intended for research and analytical applications. Gemcitabine (LY 188011) is a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent. Gemcitabine inhibits DNA synthesis and repair, resulting in autophagyand apoptosis .

HY-17026E

Gemcitabine triphosphate trisodium dFdCTP trisodium	Drug Metabolite DNA/RNA Synthesis Apoptosis	Cancer
Gemcitabine triphosphate (dFdCTP) trisodium is the active metabolite of Gemcitabine (HY-17026). The mechanism of Gemcitabine triphosphate trisodium cell-killing is its competition with cytidine triphosphate during DNA replication, which results in the inhibition of chain elongation. Gemcitabine triphosphate trisodium shows a K_i of 11.2 μM against DNA polymerase α and 14.4 μM against DNA polymerase ε. Gemcitabine triphosphate trisodium partially inhibits dCMP deaminase and acts as a substrate for DNA synthesis to incorporate into cellular DNA and RNA. Gemcitabine triphosphate trisodium disrupts DNA and RNA synthesis, arrests cell cycle in G0/G1 and S phases, triggers apoptosis, reduces tumor cell proliferation. Gemcitabine triphosphate trisodium can be used for the research of pancreatic cancer and non-small cell lung cancer .

HY-13672

LY2334737 2 Publications Verification	Nucleoside Antimetabolite/Analog Enterovirus	Infection Cancer
LY2334737 is an nucleoside analog and is an orally active proagent of Gemcitabine. LY2334737 exhibits inhibitory activity against enterovirus A71 (EV-A71) infection. LY2334737 has antiviral and anticancer effects .

HY-108932

Gemcitabine monophosphate gemcitabine 5′-phosphate	Apoptosis	Cancer
Gemcitabine monophosphate (Gemcitabine 5′-phosphate) is one of the active intermediates of Gemcitabine (HY-17026). Gemcitabine monophosphate has a synergistic anti-cancer effect and can be delivered by formulating it into nanoparticles .

HY-13561

AZM475271 M475271	Src Apoptosis	Cancer
AZM475271 (M475271) is an orally active and selective Src kinase inhibitor. AZM475271 inhibits phosphorylation of c-Src kinase, Lck, c-yes (IC₅₀s = 0.01, 0.03, 0.08 μM, respectively). AZM475271 induces apoptosis. AZM475271 reduces tumor cell proliferation and migration in vitro and in vivo, and reduces microvessel density (MVD). AZM475271 inhibits tumor growth and metastasis. AZM475271 sensitizes tumor cells to the cytotoxic effects of Gemcitabine (HY-17026) .

HY-B0003S

Gemcitabine-13C,15N2 hydrochloride LY 188011-13C,15N2 hydrochloride	Apoptosis Nucleoside Antimetabolite/Analog DNA/RNA Synthesis Autophagy	Cancer
Gemcitabine- ¹³C, ¹⁵N₂ (hydrochloride) is the ¹³C and ¹⁵N labeled Gemcitabine hydrochloride . Gemcitabine Hydrochloride (LY 188011 Hydrochloride) is a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent. Gemcitabine Hydrochloride inhibits DNA synthesis and repair, resulting in autophagyand apoptosis .

HY-16511

Upamostat 1 Publications Verification WX-671	PAI-1 Ser/Thr Protease	Infection Cancer
Upamostat (WX-671), a prodrug of WX-UK1, is an orally active serine protease inhibitor. Upamostat inhibits the urokinase-type plasminogen activator (uPA) system, blocking the plasminogen activation process mediated by it, thereby suppressing the invasion, migration and metastasis of tumor cells. Upamostat can be used in the research of metastatic breast cancer and locally advanced pancreatic cancer .

HY-N3387

Licoricidin	Apoptosis NF-κB Akt MMP	Inflammation/Immunology Cancer
Licoricidin (LCD) is isolated from Glycyrrhiza uralensis Fisch, possesses anti-cancer activities. Licoricidin (LCD) inhibit SW480 cells (IC₅₀=7.2 μM) by inducing cycle arrest, apoptosis and autophagy, and is a potential chemopreventive or chemotherapeutic agent against colorectal cancer . Licoricidin (LCD) inhibits Lung Metastasis by inhibition of tumor angiogenesis and lymphangiogenesis as well as changes in the local microenvironment of tumor tissues the anticarcinogenic effect . Licoricidin enhanced gemcitabine-induced cytotoxicity in Osteosarcoma (OS) cells by inactivation of the Akt and NF-κB pathways in vitro and in vivo . Licoricidin blocks UVA-induced photoaging via ROS scavenging, limits the activity of MMP-1, it can be considered as an active ingredient in new topically applied anti-ageing formulations .

HY-17026A

Gemcitabine triphosphate dFdCTP	Drug Metabolite DNA/RNA Synthesis Apoptosis	Cancer
Gemcitabine triphosphate (dFdCTP) is the active metabolite of Gemcitabine (HY-17026). The mechanism of Gemcitabine triphosphate cell-killing is its competition with cytidine triphosphate during DNA replication, which results in the inhibition of chain elongation. Gemcitabine triphosphate shows a K_i of 11.2 μM against DNA polymerase α and 14.4 μM against DNA polymerase ε. Gemcitabine triphosphate partially inhibits dCMP deaminase and acts as a substrate for DNA synthesis to incorporate into cellular DNA and RNA. Gemcitabine triphosphate disrupts DNA and RNA synthesis, arrests cell cycle in G0/G1 and S phases, triggers apoptosis, reduces tumor cell proliferation. Gemcitabine triphosphate can be used for the research of pancreatic cancer and non-small cell lung cancer .

HY-130812

Gemcitabine-O-Si(di-iso)-O-Mc	Drug-Linker Conjugates for ADC	Cancer
Gemcitabine-O-Si(di-iso)-O-Mc is a agent-linker conjugate for ADC with potent antitumor activity by using Gemcitabine (a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent; HY-17026), linked via the ADC linker .

HY-P99667

Ipafricept 4 Publications Verification OMP-54F28; FZD8-Fc	Wnt	Cancer
Ipafricept (OMP-54F28; FZD8-Fc) is a first class recombinant fusion protein with the extracellular part of the human frizzled-8 receptor fused to a human IgG1 Fc fragment that binds Wnt ligands, which blocks Wnt signaling. Ipafricept reduces tumor growth and results in a decrease in both liver and lung metastases combined with Gemcitabine (HY-17026) in pancreatic cancer mouse models. Ipafricept shows solid tumor inhibition activity with well tolerance, such as desmoid tumor, germ cell cancer, ovarian cancer .

HY-138253R

2′,2′-Difluorodeoxyuridine (Standard) dFdU (Standard); 2',2'-Difluoro-2'-deoxyuridine (Standard)	Drug Metabolite Reference Standards Apoptosis	Cancer
2′,2′-Difluorodeoxyuridine (Standard) is the analytical standard of 2′,2′-Difluorodeoxyuridine. This product is intended for research and analytical applications. 2’,2’-Difluorodeoxyuridine (dFdU) is the main metabolite of Gemcitabine (HY-17026). 2’,2’-Difluorodeoxyuridine causes a concentration- and schedule- dependent radiosensitising effect in vitro. 2’,2’-Difluorodeoxyuridine arrests cell cycle at the early S phase and induces apoptosis in cancer cells.

HY-138253S

2′,2′-Difluorodeoxyuridine-13C,15N2 dFdU-¹³C,¹⁵N₂; 2',2'-Difluoro-2'-deoxyuridine-¹³C,¹⁵N₂	Isotope-Labeled Compounds Drug Metabolite Apoptosis	Others
2′,2′-Difluorodeoxyuridine- ¹³C, ¹⁵N₂ (dFdU- ¹³C, ¹⁵N₂) is a ¹³C- and ¹⁵N-labeled compound. 2’,2’-Difluorodeoxyuridine (dFdU) is the main metabolite of Gemcitabine (HY-17026). 2’,2’-Difluorodeoxyuridine causes a concentration- and schedule- dependent radiosensitising effect in vitro. 2’,2’-Difluorodeoxyuridine arrests cell cycle at the early S phase and induces apoptosis in cancer cells .

HY-113314

AFMK	Endogenous Metabolite	Cancer
AFMK, antioxidant metabolite of Melatonin, attenuates X-ray-induced oxidative damage to DNA, proteins and lipids in mice. AFMK is a poorer scavenger. The pK_a of AFMK at physiological pH is 8.7. Antioxidant capacity . AFMK improves the anti-tumor effect of Gemcitabine in PANC-1 cells through the modulation of apoptotic pathway .

HY-130818

N-(5-Hydroxypentyl)maleimide	ADC Linker	Cancer
N-(5-Hydroxypentyl)maleimide is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs), such as Gemcitabine-O-Si(di-iso)-O-Mc (HY-130812) ) .

HY-100195

SAR-020106 1 Publications Verification	Checkpoint Kinase (Chk)	Cancer
SAR-020106 is an ATP-competitive, potent, and selective CHK1 inhibitor with an IC₅₀ of 13.3 nM for human CHK1. SAR-020106 shows excellent selectivity over CHK2. SAR-020106 significantly enhances the cell killing of Gemcitabine and SN38 by 3- to 29-fold in several colon tumor lines and in a p53-dependent fashion. SAR-020106 can enhance antitumor activity with selected anticancer agents .

HY-171414

MC-VC-PAB-O-Gemcitabine	Antibiotic Bacterial	Infection
MC-VC-PAB-O-Gemcitabine is a linker-antibiotic intermediate, which is part of the antibody-antibiotic conjugate (AAC) molecule. MC-VC-PAB-O-Gemcitabine is conjugated with the linker and the antibiotic Gemcitabine (HY-17026). MC-VC-PAB-O-Gemcitabine can be used to study the immunotherapy of bacterial infections and the development of new antibacterial drugs .

HY-15883

GNE-900	Checkpoint Kinase (Chk) Apoptosis	Cancer
GNE-900 is a an ATP-competitive, selective, and orally active ChK1 inhibitor with IC₅₀s of 0.0011, 1.5 μM for ChKl, ChK2, respectively. GNE-900 abrogates the G2-M checkpoint, enhances DNA damage, and induces Apoptosis. Gemcitabine (HY-17026) and GNE-900 administration shows anti-tumor activity .

HY-13538A

Gemcitabine elaidate hydrochloride 5 Publications Verification CP-4126 hydrochloride; CO-101 hydrochloride; gemcitabine 5'-elaidate hydrochloride	Nucleoside Antimetabolite/Analog Autophagy Apoptosis	Cancer
Gemcitabine elaidate (CP-4126) hydrochloride is lipophilic pro-agent of Gemcitabine. Gemcitabine elaidate hydrochloride is converted to Gemcitabine by esterases in order to be phosphorylated. Gemcitabine elaidate hydrochloride exhibits anti-tumor activity .

HY-156027

SIRT6-IN-3	Sirtuin HDAC Akt mTOR Ribosomal S6 Kinase (RSK) ERK	Neurological Disease Inflammation/Immunology Endocrinology Cancer
SIRT6-IN-3 (compound 8a) is a selective inhibitor of SIRT6 (IC₅₀=7.49 μM). SIRT6-IN-3 inhibits pancreatic ductal adenocarcinoma (PDAC) cells proliferation and induces apoptosis. SIRT6-IN-3 increases the sensitivity of cancer cells to gemcitabine (HY-17026) via blocking the DNA damage repair pathway. SIRT6-IN-3 is used in pancreatic cancer research .

HY-B0003R

Gemcitabine hydrochloride (Standard) LY 188011 hydrochloride (Standard)	Reference Standards DNA/RNA Synthesis Nucleoside Antimetabolite/Analog Autophagy Apoptosis	Cancer
Gemcitabine (hydrochloride) (Standard) is the analytical standard of Gemcitabine (hydrochloride). This product is intended for research and analytical applications. Gemcitabine Hydrochloride (LY 188011 Hydrochloride) is a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent. Gemcitabine Hydrochloride inhibits DNA synthesis and repair, resulting in autophagyand apoptosis .

HY-B0003AS

*(2S)-Gemcitabine-13C,15N2 hydrochloride*	Isotope-Labeled Compounds	Others
(2S)-Gemcitabine- ¹³C, ¹⁵N₂ (hydrochloride) is the ¹³C and ¹⁵N labeled (2S)-Gemcitabine hydrochloride .

HY-100709

ZPCK SL-01	Nucleoside Antimetabolite/Analog DNA/RNA Synthesis Autophagy Apoptosis	Cancer
ZPCK is an oral active proagent of gemcitabine that was designed for improved oral bioavailability .

HY-16138

Ivaltinostat CG-200745	HDAC MDM-2/p53 Apoptosis	Cancer
Ivaltinostat (CG-200745) is an orally active, potent pan-HDAC inhibitor which has the hydroxamic acid moiety to bind zinc at the bottom of catalytic pocket. Ivaltinostat inhibits deacetylation of histone H3 and tubulin. Ivaltinostat induces the accumulation of p53, promotes p53-dependent transactivation, and enhances the expression of MDM2 and p21 (Waf1/Cip1) proteins. Ivaltinostat enhances the sensitivity of Gemcitabine-resistant cells to Gemcitabine (HY-16138) and 5-Fluorouracil (5-FU; HY-90006). Ivaltinostat induces apoptosis and has anti-tumour effects .

HY-16138A

Ivaltinostat formic CG-200745 formic	HDAC MDM-2/p53 Apoptosis	Inflammation/Immunology Endocrinology Cancer
Ivaltinostat (CG-200745) formic is an orally active, potent pan-HDAC inhibitor which has the hydroxamic acid moiety to bind zinc at the bottom of catalytic pocket. Ivaltinostat formic inhibits deacetylation of histone H3 and tubulin. Ivaltinostat formic induces the accumulation of p53, promotes p53-dependent transactivation, and enhances the expression of MDM2 and p21 (Waf1/Cip1) proteins. Ivaltinostat formic enhances the sensitivity of Gemcitabine-resistant cells to Gemcitabine (HY-16138) and 5-Fluorouracil (5-FU; HY-90006). Ivaltinostat formic induces apoptosis and has anti-tumour effects .

HY-115528

FF-10502	Nucleoside Antimetabolite/Analog DNA/RNA Synthesis	Cancer
FF-10502, a structural analog of Gemcitabine, is a pyrimidine nucleoside antimetabolite. FF-10502 inhibits DNA polymerase α and β. FF-10502 shows beneficial anticancer activity via a mechanism of action on dormant cells .

HY-108932A

Gemcitabine monophosphate disodium gemcitabine 5′-phosphate disodium	Apoptosis	Cancer
Gemcitabine monophosphate (Gemcitabine 5′-phosphate) is one of the active intermediates of Gemcitabine (HY-17026). Gemcitabine monophosphate has a synergistic anti-cancer effect and can be delivered by formulating it into nanoparticles .

HY-106777

Cyclopentenylcytosine 1 Publications Verification CPEC; NSC 375575	DNA/RNA Synthesis Nucleoside Antimetabolite/Analog Apoptosis Necroptosis Influenza Virus HSV	Infection Cancer
Cyclopentenylcytosine (CPEC), a carbocyclic nucleoside analog of cytosine, is a potent inhibitor of CTP synthetase and causes depletion of CTP and dCTP pools. Cyclopentenylcytosine shows broad-spectrum (both DNA and RNA viruses) antiviral activity. Cyclopentenyl cytosine increases Gemcitabine (HY-17026) radiosensitisation in human pancreatic cancer cells. Cyclopentenylcytosine shows effective antiviral activity in the Ad5/NZW rabbit ocular replication model and shows anti-tumor activity in various tumor xenografts model. Cyclopentenylcytosine can be used for the study of infection and cancer .

HY-139901

Chk1-IN-6	Checkpoint Kinase (Chk)	Cancer
Chk1-IN-6 is a selective and orally active Chk1 inhibitor with an IC₅₀ of 16.1 nM. Chk1-IN-6 shows antiproliferative activity of MV-4-11 cells. Chk1-IN-6 exerts effective response in the MV-4-11 xenograft mouse model. Chk1-IN-6 exhibits synergistic anticancer effect with Gemcitabine (HY-17026). Chk1-IN-6 can be used in the research of cancers such as acute myeloid leukemia and colorectal adenocarcinoma .

HY-103367

CHK1-IN-7	Checkpoint Kinase (Chk)	Cancer
CHK1-IN-7 (Compound 10c) is a potent human CHK1 inhibitor. CHK1-IN-7 shows no single agent effect, potentiates the antiproliferative effect of Gemcitabine HY-17026 in both prostate and breast cancer cell lines. CHK1-IN-7 can be used for the research of cancer .

HY-174448

WEE1-IN-12	Wee1	Cancer
WEE1-IN-12 (Compound 87) is a Wee1 kinase inhibitor with an IC₅₀ of 2.0 nM. WEE1-IN-12 can inhibit the proliferation of HT29 cells (IC₅₀: 1.07 μM), and when used in combination with Gemcitabine (HY-17026), the effect is better (IC₅₀: 0.34 μM). WEE1-IN-12 can be used in the research of tumors such as colon cancer .

HY-B0003A

*1'-epi Gemcitabine* hydrochloride** 1'-epi LY 188011 hydrochloride	Nucleoside Antimetabolite/Analog Apoptosis DNA/RNA Synthesis	Cancer
1'-epi Gemcitabine hydrochloride is the isomer of Gemcitabine hydrochloride (HY-B0003), and can be used as an experimental control. Gemcitabine Hydrochloride (LY 188011 Hydrochloride) is a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent. Gemcitabine Hydrochloride inhibits DNA synthesis and repair, resulting in autophagyand apoptosis .

HY-17026S

Gemcitabine-13C,15N2 LY 188011-¹³C,¹⁵N₂	Isotope-Labeled Compounds Nucleoside Antimetabolite/Analog DNA/RNA Synthesis Autophagy Apoptosis	Cancer
antimetabolite and an antineoplastic agent. Gemcitabine inhibits DNA synthesis and repair, resulting in autophagyand apoptosis .

HY-178021

HDAC1-IN-11	HDAC DNA/RNA Synthesis Apoptosis RAD51 Caspase	Cancer
HDAC1-IN-11 (Compound 6) is a HDAC1 inhibitor with an IC₅₀ of 106.6  nM. HDAC1-IN-11 inhibits the expression of Sp1 and RAD51, thereby inducing Caspase-dependent apoptosis. HDAC1-IN-11 has antitumor activity and sensitizes Etoposide (HY-13629) and Gemcitabine (HY-17026), promoting synergistic death of NSCLC cells through the inhibition of homologous recombination and non-homologous end joining (NHEJ) pathways involved in DNA DSB repair. HDAC1-IN-11 can be used for chemotherapy of cancers like NSCLC research .

HY-178022

HDAC6-IN-63	HDAC Apoptosis Caspase RAD51 DNA/RNA Synthesis	Cancer
HDAC6-IN-63 (Compound 7) is an orally active HDAC6 inhibitor with an IC₅₀ of 145  nM. HDAC6-IN-63 inhibits the expression of Sp1 and RAD51, thereby inducing Caspase-dependent apoptosis. HDAC6-IN-63 has antitumor activity and sensitizes Etoposide (HY-13629) and Gemcitabine (HY-17026), promoting synergistic death of NSCLC cells through the inhibition of homologous recombination and non-homologous end joining (NHEJ) pathways involved in DNA DSB repair. HDAC6-IN-63 can be used for chemotherapy of cancers like NSCLC research .

HY-178293

N-Succinimidyl 3-maleimidopropionate	Drug-Linker Conjugates for ADC	Cancer
N-Succinimidyl 3-maleimidopropionate (Compound MC1) is a Glucuronide-Gemcitabine conjugate. N-Succinimidyl 3-maleimidopropionate can be used to synthesize ADCs (such as cAc10ec-MC1). N-Succinimidyl 3-maleimidopropionate can be used in Hodgkin's lymphoma research .

HY-161383

CHK1-IN-9	Checkpoint Kinase (Chk)	Cancer
CHK1-IN-9 (compound 11) is an orally active CHK1 inhibitor with an IC₅₀ value of 0.55 nM. CHK1-IN-9 can enhance the effect of DNA-damaging drugs on tumor cells. CHK1-IN-9 has synergistic anticancer effects with Gemcitabine (HY-17026) .

HY-15882

GNE-783	Endogenous Metabolite	Cancer
GNE-783 is a selective CHK1 inhibitor that enhances the activity of gemcitabine. GNE-783 improves the efficacy of anti-metabolite DNA damage drugs by inactivating S-phase and G2-phase cell cycle checkpoints following DNA damage. GNE-783 selectively enhances the chemical synergy of certain drugs in different tumor types, for example, enhancing the activity of temozolomide only in melanoma cell lines .

HY-155222

TW9	Epigenetic Reader Domain HDAC	Cancer
TW9 is a potent dual inhibitor simultaneously targeting BET and HDAC proteins with K_Ds of 0.069 μM, 0.231 μM for BRD4(1), BRD4(2), and an IC₅₀ of 0.29 μM for HDAC1, respectively. TW9 is a newly generated adduct of the BET inhibitor (+)-JQ1 (HY-13030) and class I HDAC inhibitor CI994 (HY-50934). TW9 shows high potency in suppressing tumor growth in pancreatic ductal adenocarcinoma (PDAC). TW9 improves the efficacy of the chemotherapeutic agent Gemcitabine (HY-17026) .

HY-W766239

*1'-Epi Gemcitabine-3',5'-Dibenzoate-13C,15N2*	Isotope-Labeled Compounds	Others
1'-Epi Gemcitabine-3',5'-Dibenzoate- ¹³C, ¹⁵N₂ is the ¹³C- and ¹⁵N-labeled 1'-Epi Gemcitabine-3',5'-Dibenzoate.

HY-167855S

*1’-Epi Gemcitabine* hydrochloride-13C,15N2**	Isotope-Labeled Compounds P2Y Receptor	Inflammation/Immunology
1’-Epi Gemcitabine hydrochloride- ¹³C, ¹⁵N₂ is the ¹³C- and ¹⁵N-labeled MRS4833 (HY-167855). MRS4833 (compound 15) is an orally active, potent, competitive P2Y14R antagonist with an of IC₅₀ of 5.92 nM for hP2Y14R and an IC₅₀ of 4.8 nM for mP2Y14R. MRS4833 reduces airway eosinophilia in a protease-mediated asthma model and reverses chronic neuropathic pain in a mouse CCI model .

HY-178451

NQO1-responsive prodrug	Apoptosis	Cancer
NQO1-responsive prodrug is a prodrug of Gemcitabine (dFdC) (HY-17026) with anti-cancer effect. NQO1-responsive prodrug remains stable in plasma and liver/intestinal S9 fractions, releasing dFdC in an NQO1-dependent manner. NQO1-responsive prodrug induces S-phase arrest and apoptosis. NQO1-responsive prodrug inhibits tumor growth in an A549 xenograft mouse model. NQO1-responsive prodrug can be used for breast and non-small cell lung cancer (NSCLC) research .

Cat. No.	Product Name	Target	Research Area

HY-P11781

HW12	Drug Derivative	Cancer
HW12 is a random peptide containing an N-terminal cysteine and is not an EGFR ligand. HW12 can serve as a control for GE11 (HY-P10128)-conjugated mixed micelles targeting EGFR. HW12 is applicable to pancreatic cancer-related research .

Cat. No.	Product Name	Target	Research Area	Image

HY-P9964

Necitumumab 11F8; IMC-11F8; LY3012211	EGFR	Cancer
Necitumumab (11F8; IMC-11F8; LY3012211) is a human IgG monoclonal antibody directed against EGFR. Necitumumab binds to the EGF binding site of EGFR, blocks ligand binding, neutralizes ligand-induced EGFR phosphorylation and downstream signaling, induces EGFR internalization and degradation, and mediates antibody-dependent cellular cytotoxicity (ADCC) in EGFR-expressing cells. Necitumumab enhances antitumour activity in combination with Gemcitabine (HY-17026) and Cisplatin (HY-17394) in murine non-small-cell lung cancer xenograft models. Necitumumab can be used in research on cancers such as non-small cell lung cancer and colorectal cancer .

HY-P99667

Ipafricept 4 Publications Verification OMP-54F28; FZD8-Fc	Wnt	Cancer
Ipafricept (OMP-54F28; FZD8-Fc) is a first class recombinant fusion protein with the extracellular part of the human frizzled-8 receptor fused to a human IgG1 Fc fragment that binds Wnt ligands, which blocks Wnt signaling. Ipafricept reduces tumor growth and results in a decrease in both liver and lung metastases combined with Gemcitabine (HY-17026) in pancreatic cancer mouse models. Ipafricept shows solid tumor inhibition activity with well tolerance, such as desmoid tumor, germ cell cancer, ovarian cancer .

HY-P991883

Metuzumab Licartin; Metuximab; Mehuzumab	Apoptosis CDK Caspase Bcl-2 Family	Cancer
Metuzumab (Licartin) is a human-mouse chimeric IgG1 monoclonal antibody targeting CD147. Metuzumab induces Apoptosis, reduces levels of Cyclin D1, full-length Caspase-3, and Bcl-2, and increases Bax expression. Metuzumab enhances the sensitivity of non-small cell lung cancer (NSCLC) cells to Gemcitabine (HY-17026). Metuzumab is applicable for research on hepatocellular carcinoma and non-small cell lung cancer [1] [2]_.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-17026E

Gemcitabine triphosphate trisodium dFdCTP trisodium	Structural Classification Natural Products Classification of Application Fields Endogenous metabolite Disease Research Fields Source Classification Cancer	Drug Metabolite DNA/RNA Synthesis Apoptosis
Gemcitabine triphosphate (dFdCTP) trisodium is the active metabolite of Gemcitabine (HY-17026). The mechanism of Gemcitabine triphosphate trisodium cell-killing is its competition with cytidine triphosphate during DNA replication, which results in the inhibition of chain elongation. Gemcitabine triphosphate trisodium shows a K_i of 11.2 μM against DNA polymerase α and 14.4 μM against DNA polymerase ε. Gemcitabine triphosphate trisodium partially inhibits dCMP deaminase and acts as a substrate for DNA synthesis to incorporate into cellular DNA and RNA. Gemcitabine triphosphate trisodium disrupts DNA and RNA synthesis, arrests cell cycle in G0/G1 and S phases, triggers apoptosis, reduces tumor cell proliferation. Gemcitabine triphosphate trisodium can be used for the research of pancreatic cancer and non-small cell lung cancer .

HY-N3387

Licoricidin	Structural Classification Flavonoids Classification of Application Fields Leguminosae Flavanols Plants Glycyrrhiza uralensis Fisch. Inflammation/Immunology Disease Research Fields Source Classification	Apoptosis NF-κB Akt MMP
Licoricidin (LCD) is isolated from Glycyrrhiza uralensis Fisch, possesses anti-cancer activities. Licoricidin (LCD) inhibit SW480 cells (IC₅₀=7.2 μM) by inducing cycle arrest, apoptosis and autophagy, and is a potential chemopreventive or chemotherapeutic agent against colorectal cancer . Licoricidin (LCD) inhibits Lung Metastasis by inhibition of tumor angiogenesis and lymphangiogenesis as well as changes in the local microenvironment of tumor tissues the anticarcinogenic effect . Licoricidin enhanced gemcitabine-induced cytotoxicity in Osteosarcoma (OS) cells by inactivation of the Akt and NF-κB pathways in vitro and in vivo . Licoricidin blocks UVA-induced photoaging via ROS scavenging, limits the activity of MMP-1, it can be considered as an active ingredient in new topically applied anti-ageing formulations .

HY-17026A

Gemcitabine triphosphate dFdCTP	Structural Classification Natural Products Classification of Application Fields Endogenous metabolite Disease Research Fields Source Classification Cancer	Drug Metabolite DNA/RNA Synthesis Apoptosis
Gemcitabine triphosphate (dFdCTP) is the active metabolite of Gemcitabine (HY-17026). The mechanism of Gemcitabine triphosphate cell-killing is its competition with cytidine triphosphate during DNA replication, which results in the inhibition of chain elongation. Gemcitabine triphosphate shows a K_i of 11.2 μM against DNA polymerase α and 14.4 μM against DNA polymerase ε. Gemcitabine triphosphate partially inhibits dCMP deaminase and acts as a substrate for DNA synthesis to incorporate into cellular DNA and RNA. Gemcitabine triphosphate disrupts DNA and RNA synthesis, arrests cell cycle in G0/G1 and S phases, triggers apoptosis, reduces tumor cell proliferation. Gemcitabine triphosphate can be used for the research of pancreatic cancer and non-small cell lung cancer .

HY-113314

AFMK	Alkaloids Classification of Application Fields Other Alkaloids Endogenous metabolite Disease Research Fields Source Classification Cancer	Endogenous Metabolite
AFMK, antioxidant metabolite of Melatonin, attenuates X-ray-induced oxidative damage to DNA, proteins and lipids in mice. AFMK is a poorer scavenger. The pK_a of AFMK at physiological pH is 8.7. Antioxidant capacity . AFMK improves the anti-tumor effect of Gemcitabine in PANC-1 cells through the modulation of apoptotic pathway .

Cat. No.	Product Name	Chemical Structure

HY-B0003S

Gemcitabine-13C,15N2 hydrochloride
Gemcitabine- ¹³C, ¹⁵N₂ (hydrochloride) is the ¹³C and ¹⁵N labeled Gemcitabine hydrochloride . Gemcitabine Hydrochloride (LY 188011 Hydrochloride) is a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent. Gemcitabine Hydrochloride inhibits DNA synthesis and repair, resulting in autophagyand apoptosis .

HY-138253S

2′,2′-Difluorodeoxyuridine-13C,15N2

2′,2′-Difluorodeoxyuridine- ¹³C, ¹⁵N₂ (dFdU- ¹³C, ¹⁵N₂) is a ¹³C- and ¹⁵N-labeled compound. 2’,2’-Difluorodeoxyuridine (dFdU) is the main metabolite of Gemcitabine (HY-17026). 2’,2’-Difluorodeoxyuridine causes a concentration- and schedule- dependent radiosensitising effect in vitro. 2’,2’-Difluorodeoxyuridine arrests cell cycle at the early S phase and induces apoptosis in cancer cells .

HY-B0003AS

*(2S)-Gemcitabine-13C,15N2 hydrochloride*
(2S)-Gemcitabine- ¹³C, ¹⁵N₂ (hydrochloride) is the ¹³C and ¹⁵N labeled (2S)-Gemcitabine hydrochloride .

HY-17026S

Gemcitabine-13C,15N2
antimetabolite and an antineoplastic agent. Gemcitabine inhibits DNA synthesis and repair, resulting in autophagyand apoptosis .

HY-W766239

*1'-Epi Gemcitabine-3',5'-Dibenzoate-13C,15N2*
1'-Epi Gemcitabine-3',5'-Dibenzoate- ¹³C, ¹⁵N₂ is the ¹³C- and ¹⁵N-labeled 1'-Epi Gemcitabine-3',5'-Dibenzoate.

HY-167855S

1’-Epi Gemcitabine hydrochloride-13C,15N2

1’-Epi Gemcitabine hydrochloride- ¹³C, ¹⁵N₂ is the ¹³C- and ¹⁵N-labeled MRS4833 (HY-167855). MRS4833 (compound 15) is an orally active, potent, competitive P2Y14R antagonist with an of IC₅₀ of 5.92 nM for hP2Y14R and an IC₅₀ of 4.8 nM for mP2Y14R. MRS4833 reduces airway eosinophilia in a protease-mediated asthma model and reverses chronic neuropathic pain in a mouse CCI model .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks